-
Je něco špatně v tomto záznamu ?
Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
A. Kopkova, J. Sana, T. Machackova, M. Vecera, L. Radova, K. Trachtova, V. Vybihal, M. Smrcka, T. Kazda, O. Slaby, P. Fadrus,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
15-34553A
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
31614872
DOI
10.3390/cancers11101546
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044210
- 003
- CZ-PrNML
- 005
- 20200109095606.0
- 007
- ta
- 008
- 200107s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers11101546 $2 doi
- 035 __
- $a (PubMed)31614872
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kopkova, Alena $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. alena.kopkova@ceitec.muni.cz.
- 245 10
- $a Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors / $c A. Kopkova, J. Sana, T. Machackova, M. Vecera, L. Radova, K. Trachtova, V. Vybihal, M. Smrcka, T. Kazda, O. Slaby, P. Fadrus,
- 520 9_
- $a Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sana, Jiri $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. jiri.sana@ceitec.muni.cz. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic. jiri.sana@ceitec.muni.cz.
- 700 1_
- $a Machackova, Tana $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. 375588@mail.muni.cz.
- 700 1_
- $a Vecera, Marek $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. marek.vecera@ceitec.muni.cz.
- 700 1_
- $a Radova, Lenka $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. 232848@mail.muni.cz.
- 700 1_
- $a Trachtova, Karolina $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. trachtova@mail.muni.cz.
- 700 1_
- $a Vybihal, Vaclav $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. Vybihal.Vaclav@fnbrno.cz. Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. Vybihal.Vaclav@fnbrno.cz.
- 700 1_
- $a Smrcka, Martin $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. Smrcka.Martin@fnbrno.cz. Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. Smrcka.Martin@fnbrno.cz.
- 700 1_
- $a Kazda, Tomas $u Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. tomas.kazda@mou.cz. Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno 656 53, Czech Republic. tomas.kazda@mou.cz.
- 700 1_
- $a Slaby, Ondrej $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. ondrej.slaby@ceitec.muni.cz. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic. ondrej.slaby@ceitec.muni.cz.
- 700 1_
- $a Fadrus, Pavel $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. fadrus.pavel@fnbrno.cz. Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. fadrus.pavel@fnbrno.cz.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 10 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31614872 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200107 $b ABA008
- 991 __
- $a 20200109095935 $b ABA008
- 999 __
- $a ind $b bmc $g 1480799 $s 1082880
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 11 $c 10 $e 20191012 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a 15-34553A $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20200107